Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

Table 3

Univariate and multivariate analysis for factors associated with OS.

		Overall survival
		Median, 95% CI		HR (95% CI)
Gender	Female	14.1 (0.0-29.3)
	Male	5.1 (0.0-11.8)	0.012	0.8 (0.3-1.9)	0.695
Age	<60 years	8.0 (3.8-12.1)
	≥60 years	14.0 (1.9-26.0)	0.801
Tobacco smokers	Nonsmoker	19.7 (0.1-39.4)
	Smoker	7.6 (4.5-10.7)	0.036	1.7 (0.7-4.2)	0.233
ECOG PS	0-1	16.6 (7.6-25.6)
	2+	3.5 (1.1-5.9)	<0.001	11.1 (3.8-32.1)	<0.001
Disease stage	IIIB	71.5 (N/R
	IV	6.9 (4.1-9.8)	0.001	1.2 (0.7-2.2)	0.429
Histological subtype	Carcinoid	N/R (N/R)
	Atypical	30.4 (5.6-55.2)
	Large cell	6.9 (2.6-11.3)
	Small cell	6.8 (1.2-12.5)	0.003	1.3 (0.8-2.0)	0.225
Lung metastases	Absent	10.8 (2.9-18.7)
	Present	6.9 (2.3-11.6)	0.961
Bone metastases	Absent	8.0 (5.9-10.8)
	Present	14.0 (2.8-25.2)	0.751
Pleural effusion	Absent	14.1 (1.6-26.6)
	Present	6.9 (2.3-11.6)	0.003	3.2 (1.1-9.0)	0.026
CNS metastases	Absent	19.7 (6.8-32.7)
	Present	5.1 (2.7-7.6)	0.010	2.7 (1.1-6.5)	0.028
Liver metastases	Absent	14.0 (3.1-24.8)
	Present	6.4 (0.0-14.4)	0.029	2.6 (1.0-6.6)	0.038
Adrenal metastases	Absent	8.0 (4.9-11.0)
	Present	11.6 (4.7-18.6)	0.798
CD47	Negative	8.4 (4.6-12.3)
	Positive	14.0 (0.0-57.0)	0.451	0.835 (0.3-1.9)	0.677